Oct 28 (Reuters) - Allergan Plc said on Monday it had settled a class action lawsuit brought by a group of direct purchasers of Alzheimer’s disease therapy Namenda, resolving the litigation that was set to face trial this month.
Under the agreement, the drugmaker’s Forest units will pay $750 million to the plaintiff, which will be recorded as a charge in its third-quarter results.
The company said the settlement makes no admission of wrongdoing on its part.
Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Arun Koyyur
Our Standards: The Thomson Reuters Trust Principles.